Read twice and referred to the Committee on Finance.
The bill (Preserving Patient Access to Long-Term Care Pharmacies Act) amends the Social Security Act to require PDP sponsors and MA–PD organizations in plan years 2026 and 2027 to pay long-term care (LTC) pharmacies a per‑prescription supply fee for certain Part D drugs dispensed to eligible LTC patients: $30 for 2026 and an inflation‑adjusted amount for 2027. The fee is to be paid in addition to other reimbursements and failure to pay triggers a civil money penalty of at least $10,000 per failure.
Whether a federal mandate on plan reimbursements is an appropriate tool: liberals see it as necessary to protect access; conservatives see it as overreach.
Relative to its intended legislative type, this bill is a clearly targeted substantive policy change that is well-specified in statutory terms (who pays, how much, to whom, enforcement, and reimbursement timing) and augmented by a mandated GAO study.
The bill (Preserving Patient Access to Long-Term Care Pharmacies Act) amends the Social Security Act to require PDP sponsors and MA–PD organizations in plan years 2026 and 2027 to pay long-term care (LTC) pharmacies a per‑prescription supply fee for certain Part D drugs dispensed to eligible LTC patients: $30 for 2026 and an inflation‑adjusted amount for 2027.
The fee is to be paid in addition to other reimbursements and failure to pay triggers a civil money penalty of at least $10,000 per failure.
The Secretary of HHS must repay PDP sponsors and MA organizations for the aggregate supply fees they paid via subsidies (paid no later than 18 months after the plan year ends).
On content alone, the bill is a narrowly tailored, administrative payment fix with built‑in reimbursement and a mandated GAO study — features that tend to increase chances of enactment compared with sweeping, controversial bills. However, it creates statutory payment obligations and additional federal outlays (even if temporary and reimbursed), which can prompt stakeholder pushback (insurers/plans, PBMs) and attract scrutiny from pay‑fors/budget reviewers. Passage is plausible, especially if paired with offsets or folded into a larger legislative vehicle, but not assured as a standalone statute.
Relative to its intended legislative type, this bill is a clearly targeted substantive policy change that is well-specified in statutory terms (who pays, how much, to whom, enforcement, and reimbursement timing) and augmented by a mandated GAO study. It sets a limited, time‑bounded obligation and integrates cleanly into existing statutory architecture.
Whether a federal mandate on plan reimbursements is an appropriate tool: liberals see it as necessary to protect access; conservatives see it as overreach.
These are examples from the analysis, not a ranked list of the most-affected groups.
Whether a federal mandate on plan reimbursements is an appropriate tool: liberals see it as necessary to protect access; conservatives see it as overreach.
A mainstream liberal/left-leaning observer would likely view the bill as a targeted, short-term fix to shore up access to long-term care pharmacy services for vulnerable Medicare beneficiaries.
They would welcome the explicit requirement that plans pay an additive supply fee and the civil penalty for noncompliance, and would see the GAO study as a step toward a permanent solution.
They would be concerned that the payment mechanism is temporary (two years) and that the delayed federal subsidy (up to 18 months) could create cash‑flow issues for small or rural LTC pharmacies unless safeguards are stronger.
A centrist/moderate would see this bill as a focused, pragmatic intervention to protect beneficiary access where market failures exist, and would appreciate the time limit and requirement for a GAO study.
They would also weigh concerns about federal cost, administrative complexity, and the delayed subsidy timing.
A centrist would probably lean toward conditional support if the bill included clearer funding offsets, faster repayment, and guardrails to prevent unintended market distortions.
A mainstream conservative observer would likely be skeptical of the bill because it mandates private plans to make additional payments and then uses federal subsidies to reimburse those plans, which raises concerns about federal intervention, precedent, and new spending.
They would favor market or state‑level solutions over a federal requirement and question the fiscal impact and potential for moral hazard.
They would likely oppose the measure as written unless it were significantly revised to reduce federal cost and increase plan flexibility.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, the bill is a narrowly tailored, administrative payment fix with built‑in reimbursement and a mandated GAO study — features that tend to increase chances of enactment compared with sweeping, controversial bills. However, it creates statutory payment obligations and additional federal outlays (even if temporary and reimbursed), which can prompt stakeholder pushback (insurers/plans, PBMs) and attract scrutiny from pay‑fors/budget reviewers. Passage is plausible, especially if paired with offsets or folded into a larger legislative vehicle, but not assured as a standalone statute.
The bill has not accumulated any surfaced votes yet.
Whether a federal mandate on plan reimbursements is an appropriate tool: liberals see it as necessary to protect access; conservatives see…
On content alone, the bill is a narrowly tailored, administrative payment fix with built‑in reimbursement and a mandated GAO study — featur…
Relative to its intended legislative type, this bill is a clearly targeted substantive policy change that is well-specified in statutory terms (who pays, how much, to whom, enforcement, and reimbursement timing) and aug…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.